Literature DB >> 9717974

A vigorous virus-specific CD4+ T cell response may contribute to the association of HLA-DR13 with viral clearance in hepatitis B.

H M Diepolder1, M C Jung, E Keller, W Schraut, J T Gerlach, N Grüner, R Zachoval, R M Hoffmann, C A Schirren, S Scholz, G R Pape.   

Abstract

A strong virus-specific CD4+ and CD8+ T lymphocyte response to hepatitis B virus (HBV) has been associated with viral clearance, but little is known about factors determining the individual's ability to mount such a T cell response. Recently a strong association between the HLA class II allele DR13 and a self-limited course of HBV infection has been described. In the present study of 33 patients with acute hepatitis B we show that individuals carrying HLA-DR13 mount a more vigorous CD4+ T cell response to HBV core (5706 ct/min (25th/75th percentile 3239 ct/min; 10,552 ct/min)) than patients without HLA-DR 13 (1365 ct/min (490 ct/min; 5334 ct/min); P = 0.006). However, peptide epitopes aa 50-69, aa 61-85, and aa 81-105 were recognized most frequently by both patient groups. Moreover, among 14 HBV core-specific CD4+ T cell clones from two patients with HLA-DR13, only one T cell clone was HLA-DR13-restricted. Our data suggest that the beneficial effect of the HLA-DR13 alleles on the outcome of HBV infection could be explained by a more vigorous HBV core-specific CD4+ T cell response, which may either be due to more proficient antigen presentation by the HLA-DR13 molecules themselves or a linked polymorphism in a neighbouring immunoregulatory gene.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9717974      PMCID: PMC1905031          DOI: 10.1046/j.1365-2249.1998.00665.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  20 in total

1.  Immunodominant CD4+ T-cell epitope within nonstructural protein 3 in acute hepatitis C virus infection.

Authors:  H M Diepolder; J T Gerlach; R Zachoval; R M Hoffmann; M C Jung; E A Wierenga; S Scholz; T Santantonio; M Houghton; S Southwood; A Sette; G R Pape
Journal:  J Virol       Date:  1997-08       Impact factor: 5.103

2.  Cellular immune response to hepatitis B virus-encoded antigens in acute and chronic hepatitis B virus infection.

Authors:  C Ferrari; A Penna; A Bertoletti; A Valli; A D Antoni; T Giuberti; A Cavalli; M A Petit; F Fiaccadori
Journal:  J Immunol       Date:  1990-11-15       Impact factor: 5.422

3.  Nomenclature for factors of the HLA system, 1996.

Authors:  J G Bodmer; S G Marsh; E D Albert; W F Bodmer; R E Bontrop; D Charron; B Dupont; H A Erlich; R Fauchet; B Mach; W R Mayr; P Parham; T Sasazuki; G M Schreuder; J L Strominger; A Svejgaard; P I Terasaki
Journal:  Eur J Immunogenet       Date:  1997-04

4.  Identification of immunodominant T cell epitopes of the hepatitis B virus nucleocapsid antigen.

Authors:  C Ferrari; A Bertoletti; A Penna; A Cavalli; A Valli; G Missale; M Pilli; P Fowler; T Giuberti; F V Chisari
Journal:  J Clin Invest       Date:  1991-07       Impact factor: 14.808

5.  Nonradioactive HLA class II typing using polymerase chain reaction and digoxigenin-11-2'-3'-dideoxy-uridinetriphosphate-labeled oligonucleotide probes.

Authors:  C Nevinny-Stickel; M D Bettinotti; A Andreas; M Hinzpeter; K Mühlegger; G Schmitz; E D Albert
Journal:  Hum Immunol       Date:  1991-05       Impact factor: 2.850

6.  HLA-DRB1*1301 and *1302 protect against chronic hepatitis B.

Authors:  T Höhler; G Gerken; A Notghi; R Lubjuhn; H Taheri; U Protzer; H F Löhr; P M Schneider; K H Meyer zum Büschenfelde; C Rittner
Journal:  J Hepatol       Date:  1997-03       Impact factor: 25.083

7.  Triple immunofluorescence flow cytometry, using whole blood, of CD4+ and CD8+ lymphocytes expressing CD45RO and CD45RA.

Authors:  R Gruber; C Reiter; G Riethmüller
Journal:  J Immunol Methods       Date:  1993-08-09       Impact factor: 2.303

8.  Increased frequency of HLA DR13 in hepatitis C virus carriers with persistently normal ALT levels.

Authors:  N Kuzushita; N Hayashi; K Katayama; N Hiramatsu; M Yasumaru; H Murata; Y Shimizu; T Yamazaki; H Fushimi; K Kotoh; A Kasahara; H Fusamoto; T Kamada
Journal:  J Med Virol       Date:  1996-01       Impact factor: 2.327

9.  Linkage disequilibrium between TAP2 variants and HLA class II alleles; no primary association between TAP2 variants and insulin-dependent diabetes mellitus.

Authors:  K S Rønningen; D E Undlien; R Ploski; N Maouni; R J Konrad; E Jensen; E Hornes; H Reijonen; M Colonna; D S Monos
Journal:  Eur J Immunol       Date:  1993-05       Impact factor: 5.532

10.  Decreased frequency of HLA-DRB1 13 alleles in Frenchwomen with HPV-positive carcinoma of the cervix.

Authors:  X Sastre-Garau; M N Loste; A Vincent-Salomon; M Favre; E Mouret; A de la Rochefordiere; J C Durand; E Tartour; V Lepage; D Charron
Journal:  Int J Cancer       Date:  1996-06-21       Impact factor: 7.396

View more
  23 in total

Review 1.  Genetic bases of autoimmune hepatitis.

Authors:  Albert J Czaja; Derek G Doherty; Peter T Donaldson
Journal:  Dig Dis Sci       Date:  2002-10       Impact factor: 3.199

2.  Sustained and transient oscillations and chaos induced by delayed antiviral immune response in an immunosuppressive infection model.

Authors:  Hongying Shu; Lin Wang; James Watmough
Journal:  J Math Biol       Date:  2013-01-11       Impact factor: 2.259

Review 3.  Current status and prospects of studies on human genetic alleles associated with hepatitis B virus infection.

Authors:  Fu-Sheng Wang
Journal:  World J Gastroenterol       Date:  2003-04       Impact factor: 5.742

Review 4.  The role of common protective alleles HLA-DRB1*13 among systemic autoimmune diseases.

Authors:  H Furukawa; S Oka; N Tsuchiya; K Shimada; A Hashimoto; S Tohma; A Kawasaki
Journal:  Genes Immun       Date:  2016-11-10       Impact factor: 2.676

5.  New Gene Variants Associated with the Risk of Chronic HBV Infection.

Authors:  Mengjie Fan; Jing Wang; Sa Wang; Tengyan Li; Hong Pan; Hankui Liu; Huifang Xu; Daria V Zhernakova; Stephen J O'Brien; Zhenru Feng; Le Chang; Erhei Dai; Jianhua Lu; Hongli Xi; Yanyan Yu; Jianguo Zhang; Binbin Wang; Zheng Zeng
Journal:  Virol Sin       Date:  2020-04-15       Impact factor: 4.327

6.  Immunologic evidence for lack of heterologous protection following resolution of HCV in patients with non-genotype 1 infection.

Authors:  Julian Schulze Zur Wiesch; Georg M Lauer; Joerg Timm; Thomas Kuntzen; Martin Neukamm; Andrew Berical; Andrea M Jones; Brian E Nolan; Steve A Longworth; Victoria Kasprowicz; Cory McMahon; Alysse Wurcel; Ansgar W Lohse; Lia L Lewis-Ximenez; Raymond T Chung; Arthur Y Kim; Todd M Allen; Bruce D Walker
Journal:  Blood       Date:  2007-05-02       Impact factor: 22.113

7.  Boosting immunity by antiviral drug therapy: a simple relationship among timing, efficacy, and success.

Authors:  Natalia L Komarova; Eleanor Barnes; Paul Klenerman; Dominik Wodarz
Journal:  Proc Natl Acad Sci U S A       Date:  2003-02-06       Impact factor: 11.205

8.  Association between HLA class II gene and susceptibility or resistance to chronic hepatitis B.

Authors:  Ye-Gui Jiang; Yu-Ming Wang; Tong-Hua Liu; Jun Liu
Journal:  World J Gastroenterol       Date:  2003-10       Impact factor: 5.742

Review 9.  Managing occupational risks for hepatitis C transmission in the health care setting.

Authors:  David K Henderson
Journal:  Clin Microbiol Rev       Date:  2003-07       Impact factor: 26.132

10.  Consensus siRNA for inhibition of HCV genotype-4 replication.

Authors:  Abdel Rahman N Zekri; Abeer A Bahnassy; Hanaa M Alam El-Din; Hosny M Salama
Journal:  Virol J       Date:  2009-01-27       Impact factor: 4.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.